Please provide your email address to receive an email when new articles are posted on . Milademetan failed to significantly extend PFS among patients with dedifferentiated liposarcoma, according to ...

Dedifferentiated liposarcoma is a fast-growing and more aggressive type of soft tissue sarcoma that originates as a well-differentiated sarcoma and has a typical diagnosis age of 40 to 60 years. DDLPS ...

Please provide your email address to receive an email when new articles are posted on . Administration of the MDM2 inhibitor milademetan in an intermittent dosing schedule mitigated dose-limiting ...

ROCHELLE PARK, NJ, UNITED STATES, December 4, 2024 /EINPresswire.com/ -- i3 Health ® and Oncology Data Advisor ® are pleased to announce the publication of the ...

Rain Oncology is a late-stage oncology company. Their lead product, milademetan, is an oral inhibitor of the MDM2-p53. In the past, MDM2 inhibitors have been associated with severe hematologic events.

We identified 276 patients with primary retroperitoneal WDLS and 353 patients with primary retroperitoneal DDLS who underwent resection between July 1982 and July 2021 at our institution. WDLS ...

NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, ...

Esophageal liposarcoma and fibrovascular polyps represent rare but clinically significant tumours of the oesophagus. Traditionally, fibrovascular polyps have been considered benign, pedunculated ...